Badi El Osta, MD

Assistant Professor, Hematology & Medical Oncology

Emory University School of Medicine

Office: Atlanta VA Medical Center

Email: badi.el.osta@emory.edu

Biography

A board certified in medical oncology and palliative medicine, Dr. El Osta specializes in the prevention and treatment of head and neck, and lung cancers. Since joining the Emory faculty in 2016, he has been actively involved in patient care and clinical research, as well as in the education of Emory University oncology fellows and medical residents at the Atlanta VA Medical Center.

Dr. El Osta received his MD from Saint Joseph's University School of Medicine in Beirut, Lebanon. He completed his residency at Good Samaritan Hospital in Cincinnati, Ohio. Thereafter, he completed three fellowships: Hematology/Oncology at the Medical College of Georgia in Augusta, Georgia; Investigational Cancer Therapeutics (phase 1 clinical trials) and Palliative Care at the University of Texas MD Anderson Cancer Center in Houston, Texas.

Dr. El Osta is a clinical member of the Discovery and Developmental Therapeutics research program at the Winship Cancer Institute of Emory University. He serves as a member of the Biomedical Committee of the Institutional Review Board at Emory University.

Dr. El Osta holds professional memberships with American Society of Clinical Oncology, Cancer Therapy Evaluation Program, and Eastern Cooperative Oncology Group.

Full Clinical Bio >>

Research

Dr. El Osta is building his research portfolio to focus on biology and tumor microenvironment, conduct of therapeutic clinical trials and improving outcomes in patients with lung, and head and neck cancers.

He is investigating the clinical and molecular biology characteristics of patients with lung adenocarcinoma using the Lung Cancer Molecular Consortium database. In addition to determining the frequency of mutations, he will evaluate specifically the impact of KRAS mutations and its associated co-mutations on survival in these patients.

He is designing phase 1 clinical trials by translating strategies to alleviate the mechanisms of resistance to immune and targeted therapies in refractory cancers and to identify biomarkers to predict response to therapy. He has co-designed three investigator-initiated trials combining targeted and immune therapies in solid malignancies, one of them was recently presented at American Society of Clinical Oncology's annual meeting and published in Cancer Discovery.

He is also interested in the economics of phase 1 clinical trials and the identification of cost-control strategies to develop a more cost-effective organizational model.

Publications